
This phase I/II nonrandomized, open-label study was designed to assess the safety and benefit of sequencing irinotecan (Camptosar, CPT-11) plus paclitaxel (Taxol) immediately after cisplatin (Platinol)/etoposide (VePesid,

Your AI-Trained Oncology Knowledge Connection!


Published: July 2nd 2000 | Updated: